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T Interval Duration
emains a Major Risk Factor
n Long QT Syndrome Patients*
manuela T. Locati, MD, PHD, FESC
erugia and Milan, Italy
lmost 50 years after the first description of congenital long
T syndrome (LQTS), where QT interval prolongation
as recognized as the hallmark of a new pathologic entity
ssociated with sudden cardiac death (1), the simple linear
easurement of QT interval still stands as the strongest
ndependent predictor of cardiac events in LQTS patients.
Prolonged corrected QT interval (QTc) was a powerful
ndependent risk factor for cardiac event (syncope or cardiac
rrest) since the initial analysis of patients enrolled in the
nternational LQTS Registry (2–3). Subsequent analyses
onfirmed that finding (4–10). Incremental changes of QT
nterval carried higher risk for sudden death, and a cutoff of
Tc 500 ms consistently identified higher-risk patients.
Most analyses of the International LQTS Registry were
ased on QT interval measured on the first available
lectrocardiogram (ECG) (6–8). This was done to avoid
ossible selection bias, because symptomatic patients tended
o have more ECG recordings than asymptomatic subjects,
nd to limit possible effects of concomitant therapies, which
ere less likely to be present in the earliest ECG.
See page 1047
The study by Goldenberg et al. (11) in this issue of the
ournal first evaluated possible incremental benefit of
ollow-up ECG on risk stratification. Its main results were
hat maximum QTc, rather than baseline QTc, was better
orrelated with risk of cardiac events during follow-up and
hat an increased number of ECG tracings may improve risk
tratification. The major clinical implications are that serial
CG tracings should be routinely obtained during clinical
ollow-up of LQTS patients and that changes of QT
nterval duration may be monitored to evaluate the effect of
herapies in LQTS patients.
GE- AND GENDER-RELATED
IFFERENCES OF QT INTERVAL DURATION
he variability of QT interval in serial tracings remains
argely unexplained. Its origin is probably multifactorial.
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Division of Cardiology, Department of Clinical and Experimentalc
edicine, University of Perugia, Perugia; and the “A. De Gasperis” Cardiovascular
epartment, Niguarda Hospital, Milan, Italy.ge-dependent gender-related effects affect QT interval
ariability. Specifically, gender differences in QTc are not
resent during infancy, and QTc decreases in boys, but not
n girls, during adolescence (12,13).
The present study could not determine the effect of
ime-dependent QTc changes during adolescence on risk of
ardiac events. However, previous studies suggested that
ardiac events may decrease in LQTS boys after puberty in
arallel with decreased QT duration, although LQTS girls
emained at higher risk of cardiac events even in adult life
6–8).
Normal adult women have longer QT intervals than men;
he normal cut-off for QTc interval is 440 ms for men and
60 ms for women (14). As to heart rate dependence of the
T interval, adult women have longer QT intervals at
onger cycle lengths than men (15).
Higher female prevalence was observed in torsade de
ointes associated with acquired prolonged repolarization,
egardless of agents provoking QT prolongation. Recurrent
elf-terminating torsade de pointes may be more frequent
mong women than men, owing to unknown gender dif-
erences in electrophysiologic substrate (16).
These phenomena may account for the apparent gender
mbalance steadily observed among patients referred to the
nternational LQTS Registry (2,3,6–8). Diagnosis of
QTS may be more likely in women, with later onset of
epetitive nonfatal events, whereas LQTS may remain
ndetected in men, with earlier and more often fatal events.
hus, need for treatment may vary in men and women
ccording to age- and gender-dependent changes in QT
nterval duration.
Age- and gender-dependent QTc cut-off should be used
or LQTS diagnosis, particularly among adults, and QTc
hould be evaluated as a time-dependent risk factor in
QTS patients.
FFECT OF ANTIADRENERGIC
HERAPIES ON QT INTERVAL DURATION
he QTc changes in follow-up ECGs may be due to
ntiadrenergic therapies, specifically beta-blockers, largely
resent in LQTS patients, particularly among those with
ultiple cardiac events. The positive effect of antiadrenergic
herapies, beta-blockers and left cardiac sympathetic dener-
ation (LCSD), on cardiac events in LQTS patients is well
ocumented (2,3,5,17,18), although the protective effect
ay vary among genotypes (8–10,19).
Scant data are available on the effects of antiadrenergic
herapies on QT interval duration. Beta-blockers have
imited effect on normal QT interval, but the effect may be
arger in LQTS patients, with possible differences among
enotypes. A QT interval shortening was observed after
CSD, where patients with significant QTc shortening
QTc 500 ms) after LCSD had lower risk of recurrent
ardiac events (18).
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eneity in ventricular repolarization, becoming less vulner-
ble to cardiac arrhythmias, such as torsade de pointes,
robably initiated by early after-depolarization–induced ac-
ivity (20).
The present study by Goldenberg et al. (11) observed
orrelation between QT interval shortening and beneficial
ffect of antiadrenergic therapies, particularly beta-blockers.
significant QTc shortening during antiadrenergic ther-
py, and specifically QTc 500 ms, could be viewed as a
ositive finding during clinical follow-up. However, this
hould be confirmed by studies specifically evaluating the
ong-term effect of therapies on QT interval.
T INTERVAL DURATION AND LQTS GENOTYPES
n the last decade major understanding was attained of the
enetic bases of LQTS (7–10,19,21). At least 8 distinct
enetic variants have been identified (LQT1 to LQT8), and
everal specific gene mutations were described within the 5
nown mutant genes (KCNQ1, HERG, SCN5A, KCNE1,
nd KCNE2). Approximately 40% of LQTS families have
ot yet been linked to any known genes; thus, more LQTS
enes remain to be identified.
The LQTS genes encode ion channel subunits involved
n the repolarization phase of the cardiac action potential.
ost known genotypes are associated with impaired func-
ion of cardiac K channels regulating outward K cur-
ents active during late ventricular repolarization, whereas
he rare and highly malignant variant LQT3 has impaired
unction of cardiac Na channels, with late persistent
nward currents delaying ventricular repolarization (21).
Genotypes may influence the clinical course of LQTS
6–10,19). Gene-specific triggers for life-threatening ar-
hythmias have been described (9), but the genotype-
henotype correlation is not univocal, owing to different
enetrance of LQTS genes (22) and to variable expression
f different gene mutations among LQTS gene carriers (23).
The extent of QT interval prolongation varies among
QTS genotypes, with LQT3 patients having the most
ronounced QT prolongation (7,8). Besides linear QT
nterval measurements, typical morphologic abnormalities
f ventricular repolarization also have been described in
QTS, and specific T-wave patterns have been associated
ith distinct genotypes (24).
Selective effects of antiarrhythmic therapies according to
enotype were also shown in pilot studies. Patients with
QT3 may benefit from Na channel blockers, mexiletine
r flecainide, or from cardiac pacing, being at higher risk of
rrhythmia at slow heart rates (25,26). These first attempts
or gene-specific therapy are promising, although beneficial
ong-term effects of such therapies are not demonstrated yet.
Gene-specific differences in rate dependency of QT
uration also have been described (9,25,27). Preliminary
ndings indicated that LQT1 and LQT2 patients, with K
hannel abnormalities, have impaired shortening of QTuration at fast heart rate. In contrast, LQT3 patients, with
mpaired inactivation of cardiac Na channels, have further
T prolongation at longer cardiac cycles (9,25). Preliminary
ndings also indicated that distinct patterns of circadian QT
ariability are present in different LQTS genotypes. Patients
ith the LQT3 genotype, with further QT prolongation at
ow heart rate, have longer QTc duration during sleep and
ncreased incidence of cardiac events during sleep and at rest
9,27). In contrast, LQT1 and LQT2 patients appear to
ave longer QTc during the day, consistent with impaired
hortening of QT duration at fast heart rate, and higher
ncidence of cardiac events during activity or stress (9,27).
Differences in QT interval variability among genotypes
emain to be confirmed in a larger series of LQTS patients
efore they can be introduced in the clinical risk stratifica-
ion of LQTS patients.
LINICAL IMPLICATIONS AND FUTURE DIRECTIONS
he Goldenberg et al. (11) study has 2 main clinical
mplications. First, the detection of QTc of 500 ms at any
ime during follow-up identified patients at high risk for
rrhythmic events, with the clinical implication that such
atients should receive extensive work-up and effective
reatment, beta-blockers as first choice. Second, it is neces-
ary to obtain serial ECG tracings to better define the
ndividual risk, not only in symptomatic but also in asymp-
omatic LQTS patients.
More accurate age- and gender-dependent cut-off for
Tc interval among adults and evaluation of possible
eneficial effects of concurrent therapies on QTc duration
hould further improve the clinical management of LQTS
atients.
Other parameters measuring ventricular repolarization
esides linear QT interval, such as heart rate dependence of
T interval, morphologic characteristic of T-wave mor-
hology, or T-wave alternans, could contribute to better risk
tratification. Improved genotype-phenotype correlations,
ith identification of gene-specific effects of different ther-
pies on QT interval prolongation may lead to gene-specific
herapies in LQTS patients.
eprint requests and correspondence: Dr. Emanuela T. Locati,
ia Vittoria Colonna 40, 20149 Milano, Italy. E-mail:
mlocati@fastwebnet.it.
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